We are excited to announce that Eagle IP will be participating as a sponsor and exhibitor at the upcoming Life Sciences Patent Network (LSPN) North America Fall Conference in San Francisco. Our President and Managing Director, Ms. Jennifer Che, is a distinguished speaker at the event. Her talk, titled China Patent Landscape, will provide a brief overview of top China IP issues for life sciences companies and provide some strategies for how to navigate such issues (e.g., AI, post-filing data, PTA/PTE, patent linkage, export controls, and more).

Organized by Life Sciences Intellectual Property Review, this event will take place October 21-22, 2025.


Eagle IP will also be in the greater Washington DC area from October 27-31, 2025. Ms. Jennifer Che will be attending Life Sciences Masters™ 2025 (organized by IP Watchdog) in Ashburn, Virginia from October 27-29, and AIPLA 2025 Annual Meeting (organized by American Intellectual Property Law Association) in Washington DC from Oct 29-31.

If you won’t be able to attend LSPN or AIPLA, but will be in San Francisco or the Washington DC area and would like to schedule a meeting, please let us know. We look forward to seeing some of you in San Francisco and Washington DC later this month!

我們過去活動

Jennifer Che has been Recognized in IAM Strategy 300 Global Leaders 2026

2025年11月26日

Jennifer Che has been Recognized as IAM Global Leaders 2026

2025年11月4日

Jennifer Che has been listed on the IAM Strategy 300

2025年8月15日

Eagle IP Recognized as Top Tier Firm (Tier 1) for Patent Prosecution in IP Stars 2025 Patent Firms Ranking List

2025年7月3日

Dr. Jacqueline Lui, Ms. Pauli Wong, and Mr. Eddie Ho Named Patent Stars by ManagingIP

2025年6月13日

Eagle IP Ranked Among Top Tier Firms in IAM Patent 1000

2025年6月12日

Recommended Insights

Beijing IP Court Reverses CNIPA Decision and Upholds Ozempic® semaglutide patent in China as VALID based on Novo Nordisk’s Post Filing Data

2024年6月27日
Recently, all eyes have been on China as the fundamental patent covering semaglutide, the active ingredient in Ozempic® and Wegovy®, will expire on March 20, 2026. It goes without saying that generics are ramping up bigtime in China (and also around the world), preparing to manufacture and sell this blockbuster drug to one of the […]
閱讀更多 >

China Releases Details on Patent Term Extension, Deferred Examination and More in the Latest Draft Implementation Rules of the New Chinese Patent Law

2020年12月11日
The China National Intellectual Property Administration (CNIPA) is moving forward at breakneck speeds aiming to get all the necessary pieces in place for the June 1, 2021 date when the new 4th Amendment of the Patent Law will come into effect. Most recently, this means a flurry of drafts coming out from CNIPA, including, but […]
閱讀更多 >

CHINA: How Prohibiting "Illegal" Inventions Runs into Food Safety Law

2021年10月22日
Chinese Patent Law has an interesting provision that specifically prohibits patent protection on “illegal” or “immoral” inventions. What does this mean, exactly? According to Article 5.1 of the Chinese Patent Law, “no patent shall be granted for an invention that contravenes any law or social moral or that is detrimental to public interests.” On its […]
閱讀更多 >

CHINA DIVISIONAL PATENT STRATEGY: Recent Judgment Narrows What Constitutes “Different Inventions” for Divisionals

2021年12月6日
In China, patents applicants take advantage of a commonly-used divisional filing strategy to achieve a fine-tuned balance between protection scope and protection period (if used properly). Patent applicants (especially foreign applicants) widely welcome this well-established strategy, and up until now, have used it with much success. In fact, we recommend this strategy and have even […]
閱讀更多 >
Top crossarrow-right